Pluristem Announces Scientific Advance in Stem Cell Research; Evidence That PLX Cells Are Immunosuppressive
Immunosuppression is defined as the quality of a product to attenuate or suppress the effects of the immune system. Induced immunosuppression is generally practiced to prevent the body from rejecting an organ or bone marrow transplant or for the treatment of auto-immune diseases. Pluristem believes their immunosuppressive PLX cells could have significant positive implications in the development of products for a variety of therapeutic needs: regenerative medicine, physiological diseases and immune diseases. Additionally, this immune modulating property could prove important in treating or preventing immune reactions associated with transplantation.
Ora Burger PhD. V.P. of R&D at Pluristem stated: "Our PLX cells showed immune suppression characteristics during in vitro testing using Mixed Lymphocyte Reaction assay (MLR). The immunosuppressive quality is an important attribute for our first product, PLX-I, in the treatment of hematological malignancies. Additionally, it has promising indications for other applications involving the immune system."
William R. Prather RPh, MD, Sr. V.P. Corporate Development notes: "We now have evidence that our PLX cells are immunosuppressive as well as immune privileged. We believe these important characteristics underscore our belief that placenta-derived MSCs expanded three dimensionally in our PluriX(TM) bioreactor to become PLX cells are truly unique and may prove valuable in the treatment of a variety of degenerative, malignant and immune conditions."
Pluristem Life Systems, Inc. is life sciences driven Company that is developing and commercializing stem cell expansion technology products for the potential treatment of a variety of disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a three-dimensional proprietary bioreactor termed the PluriX(TM) that mimics different naturally occurring physiological environments. Pluristem expects its first product, PLX-I, will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. PLX-I is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
Safe Harbor Statement
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release, include: PLX cells are immunosuppressive; These characteristics could lead to breakthroughs in the treatment of hematopoietic cancers and immune diseases; that immunosuppressive PLX cells could have significant positive implications in the development of products for a variety of therapeutic needs: regenerative medicine, physiological diseases and immune diseases; that PLX cells possess immune suppression characteristics that may be used for other applications; that it has promising indications for other applications involving the immune system; that our proprietary PluriX(TM) bioreactor that gives us the unique capability to manufacture placenta-derived MSCs expanded three dimensionally to produce PLX cells. Factors that could prevent our forward looking statements from being achieved include: that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
Pluristem Life Systems
Dr. William Prather, 303-883-4954 (Investor)
Sr. VP Corporate Development
Segue Ventures LLC (for Pluristem Life Systems)
Craig Bird, 215-885-4981 (Investor)
Investorsâ?? Message Board:
Emerson Gerard Associates (for Pluristem Life Systems)
Jerry Jennings, 561-881-7318 (Media)
Posted: March 2007